INC.;THE BRIGHAM AND WOMEN'S HOSPITAL, INC.;EMORY UNIVERSITY;PRESIDENT AND FELLOWS OF HARVARD COLLEGE;DANA-FARBER CANCER INSTITUTE;THE BRIGHAM AND WOMENS HOSPITAL
发明人:
FREEMAN, GORDON,SHARPE, ARLENE,DORFMAN, DAVID M
申请号：
NZ60143906
公开号：
NZ601439A
申请日:
2006.06.08
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Disclosed is the use of an antibody that modulates Programmed Cell Death-I (PD-I) expression on T cells in the manufacture of a medicament for therapeutically treating cancer in a subject, wherein the antibody is an anti-Programmed Death Ligand 1 (PDLI) antibody, and wherein the subject has been selected after ex vivo measurement of the expression of PD-I on T cells in a biological sample from the subject after initial treatment of the subject with the antibody and wherein a decrease in PD-I expression indicated that the initial treatment was efficacious.
